Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Pharmedic Laboratories (Pvt.) Ltd Lahore

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000228 122 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx122product presentations
G70generic molecules
DF5dosage-form groups
TA12therapeutic areas
PKR122current price records
REG116registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage74%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPharmedic Laboratories (Pvt.) Ltd LahoreShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmedic-laboratories-pvt-ltd-lahoreGenerated 10 Aug 2026Anti-infectives45 · 37%Oncology & immunology39 · 32%CNS & mental health14 · 11%Gastrointestinal & hepatology8 · 7%Endocrine & metabolic4 · 3%Vitamins, minerals & nutrition3 · 2%Cardiovascular3 · 2%Other therapeutic areas6 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPharmedic Laboratories (Pvt.) Ltd LahoreDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmedic-laboratories-pvt-ltd-lahoreGenerated 10 Aug 2026122presentationsTablet57 · 47%Injection56 · 46%Capsule5 · 4%Suspension3 · 2%Infusion1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionPharmedic Laboratories (Pvt.) Ltd LahoreCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmedic-laboratories-pvt-ltd-lahoreGenerated 10 Aug 202690comparable productsBelow market median14 · 16%Near market median45 · 50%Above market median31 · 34%Company median price position0.0%Lowest-price equivalents10Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPharmedic Laboratories (Pvt.) Ltd LahoreCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pharmedic-laboratories-pvt-ltd-lahoreGenerated 10 Aug 2026Pharmasol (Pvt) Ltd.33 shared47% overlapMediate Pharmaceutical Pvt Ltd28 shared40% overlapNabiqasim Industries (Pvt) Ltd.,27 shared39% overlapNeutro Pharma (Pvt.) Ltd.,27 shared39% overlapBio-Labs(Pvt) Ltd26 shared37% overlapM/s. Genix Pharma (Pvt) Ltd.25 shared36% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives45 products · 37%
Oncology & immunology39 products · 32%
CNS & mental health14 products · 11%
Gastrointestinal & hepatology8 products · 7%
Endocrine & metabolic4 products · 3%
Vitamins, minerals & nutrition3 products · 2%
Cardiovascular3 products · 2%
Pain & musculoskeletal2 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antineoplastic medicines33 products · 27%
Third-generation cephalosporins15 products · 12%
Antipsychotics9 products · 7%
Antimalarials7 products · 6%
Macrolide antibacterials5 products · 4%
Nitroimidazole anti-infectives5 products · 4%
Antivirals4 products · 3%
Fluoroquinolone antibacterials4 products · 3%
Formulation footprint

Dosage forms

Tablet57 products
Injection56 products
Capsule5 products
Suspension3 products
Infusion1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CEFOTRIMCeftriaxone 4presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 PACLITAXPaclitaxel (albumin-bound nanoparticles) 4presentations 100 mg, 150 mg, 30 mg, 300 mg/50 mL · Injection #3 PHARMATREXATEMethotrexate 4presentations 10 mg, 2.5 mg, 50 mg/vial · Tablet, Injection #4 TAXIRONCefotaxime 4presentations 1000 mg/vial, 125 mg/vial, 250 mg/vial, 500 mg/vial · Injection #5 AZYTHRAAzithromycin 3presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Capsule, Tablet #6 CEFTAZCeftazidime 3presentations 1 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1416% of comparable products
Near market median45within ±5% of median
Above market median3134% of comparable products
Lowest-price equivalents10ties included
Company median price position 0.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
ONSET-8 8 mgOndansetron · Tablet · 10's PKR 28.31/tablet-83.0% vs market median MALASAN 80 mg/mLArtemether · Injection · 5x 1mL PKR 83.25/mL-55.6% vs market median REGELAN 10 mg/2 mLMetoclopramide · Injection · 10's PKR 18.90/vial/unit-54.2% vs market median BENDA 200 mgAlbendazole · Tablet · 2's PKR 9.25/tablet-40.8% vs market median Water for Injection 10 mLWater for Injection · Injection · 10ml PKR 1.20/mL-40.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Pharmasol (Pvt) Ltd.251 products · 101 generics 33shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 28shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 27shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 27shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 26shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 25shared generics
Regulatory & price activity

Observed database signals

Registration numbers116
Price-history records128
Products with price history6
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

33 results
Intelligence filter: Drug classAntineoplastic medicines Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
PACLITAX Paclitaxel (albumin-bound nanoparticles) 100 mg Injection 1’s 048095 PKR 16,650.94 PKR 16,650.94/vial/unit 51% below median
PACLITAX Paclitaxel (albumin-bound nanoparticles) 150 mg Injection 25mL x1’s vial 048012 PKR 22,571.28 — No comparator
PACLITAX Paclitaxel (albumin-bound nanoparticles) 30 mg Injection 5mL 027849 PKR 8,325.47 PKR 1,665.09/mL 18% above median
PACLITAX Paclitaxel (albumin-bound nanoparticles) 300 mg/50 mL Injection 1’s vial 068200 PKR 37,603.38 PKR 37,603.38/vial/unit Near median
PHARMACRISTINE Vincristine sulfate 1 mg/mL Injection 1mL 026406 PKR 407.02 PKR 407.02/mL 5% above median
PHARMACRISTINE Vincristine sulfate 1 mg/mL Injection 2mL 026406 PKR 730.79 PKR 365.40/mL 5% below median
PHARMAPLATIN Carboplatin 150 mg/15 mL Injection 1’s 059958 PKR 4,116.48 PKR 4,116.48/vial/unit Near median
PHARMAPLATIN Carboplatin 200 mg Injection 1's 017730 PKR 4,984.02 PKR 4,984.02/vial/unit No comparator
PHARMAURACIL Fluorouracil (5-FU) 25 mg/mL Injection 10 mL x 1’s 017729 PKR 249.74 PKR 24.97/mL Near median
PHARMAURACIL 5 Fluorouracil (5-FU) 25 mg/mL Injection 20mL x 1’s 024810 PKR 499.49 PKR 24.97/mL Near median
PLAXINOL Oxaliplatin 50 mg/vial Injection 1’s 052634 PKR 17,575.99 PKR 17,575.99/vial/unit No comparator
TOPOSIDE Etoposide 20 mg/mL Injection 5mL 026408 PKR 874.33 PKR 174.87/mL No comparator
VINBLAS Vinblastine 10 mg/vial Injection 1‘s 028103 PKR 2,536.07 PKR 2,536.07/vial/unit No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.